| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16:09 | Cathie Wood schlägt wieder zu: Star-Investorin kauft jetzt diese Aktien (BioNTech dabei) | 794 | BÖRSE ONLINE | Die Star-Investorin Cathie Wood hat die Schwächephase an den Märkten für weitere Käufe genutzt und eine Reihe spannender Aktien gekauft. Mit dabei ist unter anderem der deutsche Wert BioNTech. Fondsmanagerin... ► Artikel lesen | |
| 11:06 | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy (epinephrine nasal spray) Commercialization | 766 | GlobeNewswire (Europe) | neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million... ► Artikel lesen | |
| 13:25 | Gubra A/S: AbbVie reports Positive Phase 1 Multiple Ascending Dose Results for ABBV-295, a Long-Acting Amylin Analog | 519 | GlobeNewswire (Europe) | Gubra's partner AbbVie today announced positive topline results from the 12 and 13-weeks Phase 1 Multiple Ascending Dose (MAD) trial showing that ABBV-295 was well tolerated with a dose-dependent significant... ► Artikel lesen | |
| 13:12 | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease | 502 | GlobeNewswire (Europe) | Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally... ► Artikel lesen | |
| 13:00 | NewcelX Ltd.: NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes | 479 | PR Newswire | Collaboration Integrates Stem-Cell-Derived Islets with Targeted Immune Modulation
ZURICH, Switzerland, March 9, 2026 /PRNewswire/ -- NewcelX Ltd. ("NewcelX") (Nasdaq:... ► Artikel lesen | |
| 09:45 | Evotec-Aktie: Dieser Tag entscheidet | 470 | start-trading.de | Die Evotec-Aktie hat heute einen wichtigen Tag vor sich. Der Aktienkurs muss unbedingt die Kursmarke bei 5,40 Euro verteidigen, ansonsten wird ein neues Kursziel aktiviert werden, das dann sinkende... ► Artikel lesen | |
| 12:06 | Regeneron Pharmaceuticals, Inc.: Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients | 435 | GlobeNewswire (Europe) | Patients treated with olatorepatide achieved up to 19% body-weight loss at week 48 Regeneron's global Phase 3 registrational program to be initiated later this year TARRYTOWN, N.Y., March 09, 2026... ► Artikel lesen | |
| 13:14 | Coeptis Therapeutics: Vanderbilt Report: Coeptis / Z Squared Merger Enters Final Stretch - Closing Imminent as Institutional Tailwinds Build | 434 | ACCESS Newswire | BRISTOL, TN / ACCESS Newswire / March 9, 2026 / When Coeptis Therapeutics Holdings, Inc. (Nasdaq:COEP) and Z Squared Inc. announced their transformational merger in April 2025, the process ahead was... ► Artikel lesen | |
| 07:15 | EQS-News: Heidelberg Pharma AG: Heidelberg Pharma und HealthCare Royalty geben Änderung der bestehenden Lizenzvereinbarung und Beteiligung von Soleus Capital bekannt | 415 | EQS Group (DE) | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Vertrag
Heidelberg Pharma und HealthCare Royalty geben Änderung der bestehenden Lizenzvereinbarung und Beteiligung von Soleus Capital... ► Artikel lesen | |
| 17:39 | PTA-DD: Vidac Pharma Holding PLC: Mitteilung über Eigengeschäfte von Führungskräften gemäß Artikel 19 MAR | 366 | Dow Jones News | DJ PTA-DD: Vidac Pharma Holding PLC: Mitteilung über Eigengeschäfte von Führungskräften gemäß Artikel 19 MAR
Eigengeschäfte von Führungskräften gemäß Artikel 19 MAR
Vidac Pharma Holding PLC:... ► Artikel lesen | |
| 13:46 | Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio (pegunigalsidase alfa) | 315 | GlobeNewswire (Europe) | Approved dosing regimen reduces the burden for eligible patients, their families, and the broader healthcare system by extending infusion interval from every-two-weeks to every-four-weeks for those... ► Artikel lesen | |
| 18:36 | Regeneron-Licensed Obesity Drug Olatorepatide Shows Positive Results In Phase 3 Trial | 304 | AFX News | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals said olatorepatide, an investigational obesity treatment it licensed from Hansoh Pharmaceutical Group, delivered positive Phase 3 trial results... ► Artikel lesen | |
| 05:02 | Lobe Sciences Ltd.: Lobe Sciences Announces Appointment of Mr. Mirza Rahimani, CPA, CA as Chief Financial Officer | 303 | ACCESS Newswire | VANCOUVER, BC / ACCESS Newswire / March 9, 2026 / Lobe Sciences Ltd. (Lobe) (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE) is a Canadian public biopharmaceutical company incorporated in British Columbia, with... ► Artikel lesen | |
| 19:02 | Faron Pharmaceuticals: Update to Faron's Financial Calendar and Date of the Annual General Meeting in 2026 | 289 | ACCESS Newswire | TURKU, FINLAND / ACCESS Newswire / March 9, 2026 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies... ► Artikel lesen | |
| 12:06 | NovaBridge Biosciences: NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study | 287 | GlobeNewswire (Europe) | VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitorTopline Phase 2a data show VIS-101 provides rapid, robust and durable treatment... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| BB BIOTECH | 49,700 | 2,50 | +5,03 % | 2,25 | 23.03.2026 | |
| CSL | 88,32 | 2,61 | +2,96 % | 1,84 | 10.03.2026 | |
| AMGEN | 322,45 | 8,36 | +2,59 % | 2,52 | 15.05.2026 | |
| NOVONESIS | 48,400 | 0,87 | +1,80 % | 4,25 | 20.03.2026 | |
| GENUS | 30,800 | 0,38 | +1,23 % | 0,11 | 05.03.2026 | |
| STRYKER | 315,50 | 2,98 | +0,94 % | 0,88 | 31.03.2026 | |
| BIOMERIEUX | 95,65 | 0,90 | +0,94 % | 0,98 | 09.06.2026 | |
| BIO-TECHNE | 46,200 | 0,27 | +0,58 % | 0,08 | 13.02.2026 | |
| BRUKER | 31,500 | 0,17 | +0,54 % | 0,05 | 23.03.2026 | |
| REGENERON PHARMACEUTICALS | 668,20 | 3,02 | +0,45 % | 0,94 | 20.02.2026 |